HEALWELL's Khure Health Provides Update Highlighting Significant Acceleration in User and Life Sciences Partner Adoption of Disease Detection AI Powered Co-Pilots and Strong Physician NPS Scores
HEALWELL AI's subsidiary Khure Health reported significant growth in Q4-2024, with its AI-Powered Physician Co-Pilots helping identify over 43,000 high-risk patients across 8 clinical specialties using 132 disease-specific algorithms. This represents a 22% quarter-over-quarter growth and 500% year-over-year growth compared to Q4-2023.
The company secured 4 new Master Services Agreements with pharmaceutical partners in Q4-2024, bringing the total to 16 MSAs, including partnerships with 7 of the world's 10 largest pharmaceutical companies. Khure's physician survey revealed an Net Promoter Score (NPS) of 84, with 82% of physicians confirming improved patient care through the AI technology.
HEALWELL has now onboarded over 800 physicians using its Khure Co-Pilots, with the WELL AI Decision Support (WAIDS) Program being the fastest-growing component, representing approximately 80% of new physician onboarding in Q4.
Khure Health, sussidiaria di HEALWELL AI, ha riportato una crescita significativa nel quarto trimestre del 2024, con i suoi Co-Piloti Medici Potenziati dall'AI che hanno aiutato a identificare oltre 43.000 pazienti ad alto rischio in 8 specialità cliniche utilizzando 132 algoritmi specifici per malattia. Questo rappresenta una crescita del 22% rispetto al trimestre precedente e del 500% rispetto allo stesso trimestre del 2023.
L'azienda ha ottenuto 4 nuovi Accordi Quadro di Servizi con partner farmaceutici nel quarto trimestre del 2024, portando il totale a 16 MSA, inclusi i partenariati con 7 delle 10 più grandi aziende farmaceutiche del mondo. Un sondaggio tra i medici di Khure ha rivelato un Punteggio Net Promoter (NPS) di 84, con l'82% dei medici che conferma un miglioramento nella cura dei pazienti grazie alla tecnologia AI.
HEALWELL ha ora integrato oltre 800 medici utilizzando i suoi Co-Piloti Khure, con il Programma di Supporto Decisionale WELL AI (WAIDS) che è la componente in più rapida crescita, rappresentando circa l'80% dei nuovi medici integrati nel quarto trimestre.
Khure Health, subsidiaria de HEALWELL AI, reportó un crecimiento significativo en el cuarto trimestre de 2024, con sus Co-Pilotos Médicos Potenciados por IA ayudando a identificar a más de 43,000 pacientes de alto riesgo en 8 especialidades clínicas utilizando 132 algoritmos específicos para enfermedades. Esto representa un crecimiento del 22% en comparación con el trimestre anterior y del 500% en comparación con el cuarto trimestre de 2023.
La empresa aseguró 4 nuevos Acuerdos de Servicios Maestros con socios farmacéuticos en el cuarto trimestre de 2024, llevando el total a 16 MSA, incluidos los acuerdos con 7 de las 10 compañías farmacéuticas más grandes del mundo. Una encuesta entre los médicos de Khure reveló un Puntuación Net Promoter (NPS) de 84, con el 82% de los médicos confirmando una mejora en la atención al paciente a través de la tecnología de IA.
HEALWELL ha incorporado a más de 800 médicos utilizando sus Co-Pilotos Khure, siendo el Programa de Soporte a la Decisión WELL AI (WAIDS) el componente de más rápido crecimiento, representando aproximadamente el 80% de la incorporación de nuevos médicos en el cuarto trimestre.
HEALWELL AI의 자회사인 Khure Health는 2024년 4분기에 중요한 성장을 보고하였으며, AI 기반 의사 코파일럿이 132개의 질병별 알고리즘을 사용하여 8개의 임상 전문 분야에서 43,000명 이상의 고위험 환자를 식별하는 데 도움을 주었습니다. 이는 전 분기 대비 22% 성장과 2023년 4분기 대비 500% 성장을 나타냅니다.
회사는 2024년 4분기에 제약 파트너와 4개의 새로운 마스터 서비스 계약을 체결하여 총 16개의 MSA로 늘어났으며, 이는 세계 10대 제약회사 중 7개와의 파트너십을 포함합니다. Khure의 의사 설문조사 결과 순추천지수(NPS)가 84로 나타났으며, 82%의 의사가 AI 기술을 통해 환자 치료가 개선되었다고 확인했습니다.
HEALWELL은 현재 800명 이상의 의사를 Khure 코파일럿을 사용하여 온보딩했으며, WELL AI 의사결정 지원 프로그램(WAIDS)이 가장 빠르게 성장하는 구성 요소로, 4분기 신규 의사 온보딩의 약 80%를 차지하고 있습니다.
Khure Health, filiale de HEALWELL AI, a rapporté une croissance significative au quatrième trimestre 2024, avec ses Co-Pilotes Médecins alimentés par l'IA aidant à identifier plus de 43 000 patients à haut risque dans 8 spécialités cliniques en utilisant 132 algorithmes spécifiques à des maladies. Cela représente une croissance de 22 % par rapport au trimestre précédent et de 500 % par rapport au quatrième trimestre 2023.
L'entreprise a sécurisé 4 nouveaux Accords de Services Maîtres avec des partenaires pharmaceutiques au quatrième trimestre 2024, portant le total à 16 MSA, y compris des partenariats avec 7 des 10 plus grandes entreprises pharmaceutiques au monde. Un sondage auprès des médecins de Khure a révélé un Score Net Promoter (NPS) de 84, avec 82 % des médecins confirmant une amélioration des soins aux patients grâce à la technologie IA.
HEALWELL a désormais intégré plus de 800 médecins utilisant ses Co-Pilotes Khure, le Programme de Support à la Décision WELL AI (WAIDS) étant le composant à la croissance la plus rapide, représentant environ 80 % des nouvelles intégrations de médecins au quatrième trimestre.
Khure Health, eine Tochtergesellschaft von HEALWELL AI, berichtete im vierten Quartal 2024 von einem signifikanten Wachstum, wobei ihre KI-gestützten Arzt-Co-Piloten über 43.000 hochriskante Patienten in 8 klinischen Fachgebieten mithilfe von 132 krankheitsspezifischen Algorithmen identifizierten. Dies entspricht einem Wachstum von 22% im Quartalsvergleich und 500% im Jahresvergleich zum vierten Quartal 2023.
Das Unternehmen sicherte sich im vierten Quartal 2024 4 neue Master-Service-Verträge mit pharmazeutischen Partnern, wodurch die Gesamtzahl auf 16 MSA steigt, einschließlich Partnerschaften mit 7 der 10 größten Pharmaunternehmen der Welt. Eine Umfrage unter den Ärzten von Khure ergab einen Net Promoter Score (NPS) von 84, wobei 82% der Ärzte bestätigten, dass sich die Patientenversorgung durch die KI-Technologie verbessert hat.
HEALWELL hat nun über 800 Ärzte mit seinen Khure-Co-Piloten onboarded, wobei das WELL AI Decision Support (WAIDS) Programm die am schnellsten wachsende Komponente darstellt und etwa 80% der neuen Arzt-Onboardings im vierten Quartal ausmacht.
- 500% year-over-year growth in high-risk patient identification
- 22% quarter-over-quarter growth in Q4-2024
- Secured 4 new pharmaceutical partnerships in Q4-2024
- High NPS score of 84 with 82% physician satisfaction
- Expanded to 800 physician users
- Partnership with 7 of 10 largest pharmaceutical companies globally
- None.
- In Q4-2024, HEALWELL's subsidiary, Khure Health ("Khure") helped physicians identify over 43,000 high-risk patients with its AI-Powered Physician Co-Pilots, across 8 clinical specialities harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of
22% as compared to Q3-2024 and year-over-year growth of500% as compared to Q4-2023. - HEALWELL has executed 4 new Master Services Agreements ("MSA") with new pharmaceutical partners in Q4-2024 relating to the Khure program; bringing the total number of MSAs with life sciences partners to 16, which includes 7 of the 10 largest pharmaceutical companies in the world.
- HEALWELL recently conducted a survey of the physicians that leverage the Khure powered co-pilots that resulted in an industry outperforming Net Promoter Score (NPS) of 84, with
82% of physicians confirming that they believed that the AI powered physician Co-Pilot technology helped improve patient care. - HEALWELL has now on-boarded over 800 physicians that use its Expert-System AI-Powered Khure Physician Co-Pilots. These results include physicians that participated as part of WELL Health's network through the 'WAIDS' or 'WELL AI Decision Support' Program, which is currently the fastest growing component of the HEALWELL-Khure network.
Toronto, Ontario--(Newsfile Corp. - February 24, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to provide a corporate update highlighting its subsidiary, Khure Health Inc. ("Khure") experiencing significant acceleration in user and life sciences partner adoption of its disease detection expert-system AI powered co-pilots ("Co-Pilots"). In Q4-2024, Khure's Co-Pilots helped physicians identify over 43,000 high-risk patients across 8 clinical specialities, harnessing 132 disease specific algorithms. This figure reflected a quarter over quarter sequential growth of
Dr. Alexander Dobranowski, CEO of HEALWELL, comments, "We are incredibly proud of the momentum our Co-Pilots are experiencing. In Q4 alone, our Khure technology identified 43,000 high risk patients. This made it easier for physicians to not only identify at risk patients but also confidently triage next steps efficiently. We now have 800 physicians using this technology and experienced
We're also pleased to report that Khure has shown significant growth in terms of its commercialization efforts with pharma and life sciences companies as we've expanded our partnerships and signed new master services agreements that further integrate our disease detection algorithms into critical research and patient care workflows. At HEALWELL, we remain committed to harnessing the power of AI to drive earlier disease detection and improve patient outcomes."
Additionally, HEALWELL's Khure recently conducted a survey of its physician users that resulted in an industry outperforming Net Promoter Score (NPS) of 84, with
Figure 1. Results of Khure Health Physician Survey
| Survey Question | Overall Score |
| Overall, I'm satisfied with Khure | |
| The Khure team supports me and my practice | |
| The software saves me time | |
| The insights have positively impacted my business | |
| The software is easy to use | |
| The Khure Platform is helping me improve patient care |
HEALWELL has now on-boarded over 800 physicians that use its Khure Co-Pilots. The results above include physicians that participated as part of the WELL Health Technologies Corp. ("WELL") clinical network, which includes the expanded WELLSTAR Technologies Corp. provider network, which offers the technology under the 'WAIDS' or 'WELL AI Decision Support' program which is currently the fastest growing component of Khure's business. Physicians using WAIDS represented approximately
Don Watts, President of Khure Health, further adds, ""Physicians using our AI decision support platform consistently report high satisfaction, as reflected in our industry-leading Net Promoter Scores (NPS). They tell us that our platform is easy to use, saves them valuable time, and most importantly is helping them to improve patient care. By enabling physicians with advanced technology and supporting enhanced clinical decision-making, we're helping providers focus on what matters most - delivering the best possible outcomes for their patients."
Dr. Alexander Dobranowski
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
Forward-Looking Statements
Certain statements in this press release, constitute "forward-looking information" and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws, including statements about the potential for HEALWELL and its partners to continually leverage advancements in expert AI technologies to develop new products and services or enhance existing ones to serve its existing (and future) customer base, and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements are often, but not always, identified by words or phrases such as "possibility", "opportunity", "pending", "proposition", "continue to", "improve" or variations of such words and phrases or statements that certain future conditions, actions, events or results "will", "may", "could", "would", "should", "might" or "can" be taken, occur or be achieved, or the negative of any of these terms . Forward-looking statements are necessarily based upon management's perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by HEALWELL as of the date of such statements, are outside of HEALWELL's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward-looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: HEALWELL's ability to maintain and leverage is relationships with its commercial partners; the continued adoption of the software, tools and solutions created by HEALWELL; that HEALWELL will be successful in identifying, executing and integrating new acquisitions, investments and/or partnerships, the stability of general economic and market conditions; sufficiency of working capital and access to financing; HEALWELL's ability to comply with applicable laws and regulations; HEALWELL's continued compliance with third party intellectual property rights; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; technologies working as intended or at all; trends in customer growth and the adoption of new technologies in the industry; and that the risk factors noted below, collectively, do not have a material impact on HEALWELL's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled "Risk Factors" in HEALWELL's most recent annual information form dated April 1, 2024, which is available under HEALWELL's SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242045
FAQ
What growth did HEALWELL AI (HWAIF) achieve in patient identification during Q4-2024?
How many pharmaceutical partnerships does HEALWELL AI (HWAIF) have as of Q4-2024?
What is the physician satisfaction rate for HEALWELL AI's (HWAIF) Khure Co-Pilots?
How many physicians are using HEALWELL AI's (HWAIF) Khure Co-Pilots as of Q4-2024?
How many clinical specialties and disease algorithms does HEALWELL AI's (HWAIF) platform cover?
